Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193,679,354
-
Total 13F shares
-
78,913,089
-
Share change
-
+4,244,560
-
Total reported value
-
$197,297,266
-
Put/Call ratio
-
92%
-
Price per share
-
$2.50
-
Number of holders
-
110
-
Value change
-
+$10,900,831
-
Number of buys
-
45
-
Number of sells
-
36
Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2023
As of 31 Dec 2023,
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) was held by
110 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
78,913,089 shares.
The largest 10 holders included
Whitefort Capital Management, LP, BlackRock Inc., Two Seas Capital LP, MORGAN STANLEY, VANGUARD GROUP INC, Woodline Partners LP, Hudson Bay Capital Management LP, ADAR1 Capital Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP.
This page lists
110
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.